恶病质对信迪利单抗治疗非小细胞肺癌疗效的影响
该回顾性研究分析2019—2021年河南省人民医院62例接受抗PD-1治疗的晚期非小细胞肺癌患者,于免疫治疗前及2个周期后评估恶病质。恶病质组无进展生存期和总生存期均低于对照组,前白蛋白水平和PMMA变化率为总生存的独立影响因素。
要点
- 恶病质组无进展生存期3.8个月,低于对照组的7.6个月(P=0.006)。
- 恶病质组总生存期6.3个月,低于对照组的18.2个月(P=0.006)。
- 前白蛋白水平和PMMA变化率为总生存的独立影响因素(均P<0.05)。
核心结论
- 在抗PD-1免疫检查点抑制剂治疗中,恶病质的发生对患者预后有负面影响。
研究设计与样本
- 回顾性分析2019—2021年河南省人民医院62例接受抗PD-1治疗的晚期非小细胞肺癌患者。
- 分别于免疫治疗前、免疫治疗2个周期后评估患者恶病质情况。
- 生存分析采用Kaplan-Meier法和Log rank,多因素分析采用Cox回归模型,相关分析采用Spearman相关性分析。
主要发现
- 免疫治疗2个周期后,恶病质组和对照组PMMA分别为(14.10±4.09)cm²和(11.66±3.22)cm²,差异有统计学意义(P=0.001)。
- 全组62例患者6个月和1年生存率分别为58.6%和42.5%。
- 对照组PFS为7.6个月,高于恶病质组的3.8个月(P=0.006)。
- 高表达PD-L1患者PFS为7.1个月,长于低表达者的3.8个月(P=0.009)。
- 恶病质组OS为6.3个月,低于对照组的18.2个月(P=0.006);PD-L1高表达患者OS为14.5个月,高于低表达者的1个月(P=0.038)。
关键数值与推荐
- 前白蛋白水平和体重与恶病质有关(P<0.05)。
- 前白蛋白水平、PD-L1表达水平和PMMA变化率与患者总生存有关(均P<0.05)。
- 前白蛋白水平和PMMA变化率为总生存的独立影响因素(均P<0.05)。
- PMMA和前白蛋白水平呈负相关(r=-0.003 8,P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate whether cachexia affects the treatment effect of immune checkpoint inhibitors for non-small cell lung cancer (NSCLC). Methods: The prognosis of 62 patients with advanced NSCLC who received anti-programmed cell death-1 (PD-1) in Henan Provincial People's Hospital from 2019 to 2021 were retrospectively analyzed. The cachexia was evaluated before and after the second course of immunotherapy. Kaplan-Meier and Log rank methods were used for survival analysis, Cox regression model was used for multivariate analysis, and Spearman's correlation analysis was used for correlation analysis. Results: After the second course of immunotherapy, psoas major muscle area (PMMA) values of the cachexia group and the control group were (14.10±4.09) and (11.66±3.22) cm(2) respectively, with statistics significance (P=0.001). The level of Prealbumin and body weight were correlated with cachexia (P<0.05). The 6-month and 1-year survival rates of 62 cases in the whole group were 58.6% and 42.5%, respectively. The progression-free survival (PFS) in the control group (7.6 months) was higher than that in the cachexia group (3.8 months, P=0.006). The PFS in patients with high expression of PD-L1 (7.1 months) was longer than that of patients with low expression (3.8 months, P=0.009). The overall survival (OS) in the cachexia group (6.3 months) was lower than that in the control group (18.2 months, P=0.006). The OS in patients with high expression of PD-L1 (14.5 months) was longer than that of patients with low expression (1 months, P=0.038). The level of Prealbumin, the level of PD-L1 expression and the change rate of PMMA were related to the OS of the patients (P<0.05). The level of Prealbumin and the change rate of PMMA were the independent influencing factors of the OS (P<0.05). The PMMA and the level of Prealbumin were negatively correlated (r=-0.003 8, P<0.05). Conclusion: Cachexia has a negative impact on the outcomes of patients who received anti-PD-1 immune checkpoint inhibitor therapy. 目的: 探讨恶病质对免疫检查点抑制剂治疗非小细胞肺癌(NSCLC)疗效的影响。 方法: 回顾性分析2019—2021年河南省人民医院62例晚期NSCLC患者接受抗程序性死亡受体1(PD-1)治疗的疗效,分别于免疫治疗前、免疫治疗2个周期后评估患者恶病质情况。生存分析采用Kaplan-Meier法和Log rank,多因素分析采用Cox回归模型,相关分析采用Spearman相关性分析。 结果: 免疫治疗2个周期后,恶病质组和对照组患者的骨骼肌截面面积(PMMA)分别为(14.10±4.09)cm(2)和(11.66±3.22)cm(2),差异有统计学意义(P=0.001)。前白蛋白水平和体重与恶病质有关(P<0.05)。全组62例患者6个月和1年生存率分别为58.6%和42.5%。对照组患者无进展生存时间(PFS)高于恶病质组(分别为7.6和3.8个月,P=0.006),高表达程序性死亡受体配体1(PD-L1)患者PFS(7.1个月)长于低表达PD-L1者(3.8个月,P=0.009);恶病质组患者总生存时间(OS)低于对照组(分别为6.3和18.2个月,P=0.006);PD-L1高表达患者OS(14.5个月)高于低表达者(1个月,P=0.038)。前白蛋白水平、PD-L1表达水平和PMMA变化率与患者的总生存有关(均P<0.05),前白蛋白水平和PMMA变化率为总生存的独立影响因素(均P<0.05)。PMMA和前白蛋白水平呈负相关(r=-0.003 8, P<0.05)。 结论: 在抗PD-1的免疫检测点抑制剂治疗中恶病质的发生对患者的预后有负面影响。.
引用
- Li XQ, Zhao ZL, Hou ML, et al. [The influence of cachexia on the immunotherapy efficacy of Sintilimab for non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 34915639. doi:10.3760/cma.j.cn112152-20200916-00828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。